Robotic Mitral Valve Repair: Key Labs, Diagnostic Studies, and Nursing Considerations

Key Laboratory Values

Preoperative baseline labs are essential to identify high-risk patients and optimize surgical candidacy. 1

Normal and Critical Ranges:

Complete Blood Count: Hemoglobin >10 g/dL preferred; critical if <7 g/dL (increases transfusion risk) 2, 3
Coagulation Panel: INR <1.5, PTT <40 seconds; critical if INR >2.0 (bleeding risk) 4
Renal Function: Creatinine <1.5 mg/dL; critical if >2.0 mg/dL (affects perfusion strategy and heparin dosing) 4
Liver Function: AST/ALT <2x upper limit normal; critical if >3x (affects anticoagulation management) 4
Electrolytes: Potassium 3.5-5.0 mEq/L; critical if <3.0 or >5.5 (arrhythmia risk, especially given 28% postoperative AF rate) 2
BNP/NT-proBNP: Elevated levels indicate ventricular dysfunction; critical if markedly elevated with LVEF <25% (relative contraindication) 1

Frequency of Monitoring:

Preoperative: Complete panel within 7 days of surgery 1
Intraoperative: ACT monitoring every 30 minutes during cardiopulmonary bypass (target >480 seconds) 3
Postoperative Day 0-1: CBC, electrolytes, renal function every 6-12 hours 2
Postoperative Day 2-discharge: Daily labs until stable 2, 3
Post-discharge: INR monitoring if bioprosthetic valve (every 2-3 days until therapeutic, then weekly for 1 month, then monthly) 4

Diagnostic Studies

High-quality imaging is mandatory for patient selection and surgical planning in robotic MVR. 1, 5

Echocardiography (Most Critical):

Transthoracic Echocardiogram (TTE): Required to assess MR severity, mechanism, LVEF, LVESD, and pulmonary artery pressures 1
- Key measurements: LVEF (critical if <60%), LVESD (critical if ≥40 mm), PA systolic pressure (critical if >70 mm Hg - relative contraindication) 1
- Ideal anatomy: Posterior leaflet prolapse (>90% repair success rate expected) 1, 5
Transesophageal Echocardiogram (TEE): Warranted if TTE unclear or complex pathology; mandatory intraoperatively 1
- Intraoperative TEE: Essential for experienced TEE anesthesiologist to guide repair and assess immediate postrepair results 6, 3
- Postrepair assessment: 98-99.7% should have none/trivial MR immediately postoperatively 2, 7, 3
Baseline predischarge TTE: Mandatory to establish reference for future comparisons 6, 4
Follow-up TTE: At 3 months, then annually starting at 5 years (to detect bioprosthetic degeneration) 4

CT Angiography (Mandatory):

Chest/Abdomen/Pelvis CT with contrast: Required to assess vascular anatomy, chest wall thickness, and cardiac position 1, 5
- Critical findings: Significant aortic/iliac/femoral disease (contraindication to femoral cannulation), aorta >4 cm if using endoaortic balloon, kyphoscoliosis, pectus excavatum (compromises exposure) 1
- Stroke risk assessment: Identifies high-risk vascular anatomy; meticulous evaluation reduces stroke from 2% to 0.8% 3
- Body habitus: Thick chest walls, extreme obesity, or muscularity add distance to mitral valve (relative contraindication) 1

Cardiac Catheterization or Coronary CT:

Indicated when: Age >40 years (men) or >50 years (women), cardiac risk factors present, or any suspicion of coronary disease 1
Critical finding: Significant coronary disease requiring concomitant revascularization (increases complexity) 8

Pulmonary Function Testing:

Required for: Patients with history of chest trauma, prior chest tubes, pneumothorax, or right chest surgery 1
Rationale: Adhesions add operative time and pulmonary injury risk; may require thoracoscopy to assess safety 1
Consider: 5-mm camera port thoracoscopy if dense adhesions suspected 1

Additional Bedside Tests:

12-lead ECG: Assess for atrial fibrillation (indication for surgery if new-onset) 1, 5
Groin examination: Palpable femoral pulses, assess for hernias, large pannus, fungal infiltration (affects femoral cannulation feasibility) 1

Procedure Overview and Nursing Role

Preoperative Phase

The RN's primary role is ensuring patient optimization and team readiness for this complex, time-sensitive procedure. 6, 3

Patient Preparation:

Verify surgical consent includes robotic approach, possible conversion to sternotomy, and mitral valve replacement if repair fails 1, 6
Confirm NPO status (minimum 8 hours) 2, 3
Administer preoperative antibiotics within 60 minutes of incision (typically cefazolin 2g IV or vancomycin if MRSA risk) 3
Establish large-bore IV access (minimum 18-gauge x2) for rapid volume resuscitation if needed 2, 3
Baseline vital signs and neurological assessment: Document thoroughly for postoperative comparison (stroke occurs in 0.8-2% of cases) 3

Positioning Considerations:

Female patients: Right breast retracted toward left shoulder with adhesive sterile plastic drape; incisions at inframammary fold or lateral to breast to avoid bra irritation 1
Breast implants: Verify preoperatively that implant won't interfere with working port or left-atrial roof retraction post 1

Team Coordination:

Entire team training mandatory: Surgeon, anesthesiologist (experienced in TEE), perfusionist, scrub nurse, circulating nurse must undergo observation and proctoring 6
Equipment check: Verify da Vinci robot functionality, backup sternotomy instruments immediately available 6, 3

Intraoperative Phase

The procedure involves 3-4 cm right minithoracotomy, femoral cardiopulmonary bypass, transthoracic aortic occlusion, and robotic-assisted repair. 2, 7, 3

Surgical Technique:

Access: Right intercostal approach (4th or 5th intercostal space) 7, 3
Cannulation: Femoral arterial and venous cannulation for cardiopulmonary bypass 2, 7, 3
Myocardial protection: Transthoracic aortic cross-clamp with cardioplegia; RV not topically cooled (mitigated by lower systemic temperatures and frequent cardioplegia redosing) 1
Repair techniques: Trapezoidal/triangular resections, sliding plasties, chordal transfers/replacements, edge-to-edge approximations, ring annuloplasty in all cases 6, 2, 7
Autoknotting devices: Can reduce cross-clamp times 6

Expected Operative Times:

Early experience: Mean 272 minutes 2
Mature program: Decreases significantly with experience (P<0.0001) 3
Cardiopulmonary bypass time: Mean 156±69 minutes 8
Cross-clamp time: Mean 101±42 minutes 8

RN Circulating Role:

Monitor perfusion parameters: Communicate with perfusionist regarding ACT levels (target >480 seconds), flow rates, and systemic temperatures 3
Anticipate equipment needs: Have additional sutures, pledgets, and annuloplasty rings of various sizes immediately available 6
Document robotic console time: Track docking, operative, and undocking times for quality improvement 6, 3
Prepare for potential conversion: Sternotomy instruments must remain sterile and immediately accessible (though conversion rate is 0% in experienced centers) 7, 3

RN Scrub Role:

Consistent tableside assistance critical: Experienced scrub nurse essential for efficient instrument exchanges 6
Suture management: Polytetrafluoroethylene (PTFE) sutures used for repairs; organize by repair step 6
Specimen handling: If leaflet resection performed, send to pathology 2, 7

Anesthesia Considerations:

Intraoperative TEE: Experienced TEE anesthesiologist mandatory to guide repair and assess results 6, 3
Postrepair assessment: Must confirm none/trivial MR before chest closure (99.7% achieve this benchmark) 7, 3
De-airing protocol: Meticulous technique prevents cerebrovascular injury 6, 3

Postoperative Phase

Early recognition of complications and aggressive respiratory management are nursing priorities. 2, 3

Immediate Postoperative (ICU):

Hemodynamic Monitoring:

Arterial line monitoring: Continuous blood pressure; target MAP >65 mm Hg 2, 3
Central venous pressure: Monitor for adequate preload (target CVP 8-12 mm Hg) 2
Cardiac output monitoring: If available, optimize to >2.2 L/min/m² 3
Assess for bleeding: Inspect robotic port sites deliberately before closure; consider videoscopic re-exploration if stable patient with bleeding 6
- Transfusion rate: 82.4% require no blood products; average 2.4 units PRBC if transfused 2, 8
- Reoperation for bleeding: 2.3% rate 7

Respiratory Management:

Mean ventilator time: 32.1 hours 2
Aggressive pulmonary toilet: Incentive spirometry every 1-2 hours while awake; early mobilization reduces pleural effusion risk 5
Pain control: Multimodal analgesia (epidural or paravertebral blocks preferred) facilitates deep breathing 9

Neurological Assessment:

Hourly neuro checks first 24 hours: Stroke occurs in 0.8-2% (declining with experience); transient ischemic attacks also reported 7, 3
Immediate CT head if any focal deficits 3

Cardiac Rhythm Monitoring:

Atrial fibrillation: Occurs in 28% postoperatively 2
If cryoablation performed: 85% restore normal sinus rhythm; 5.8% require permanent pacemaker within one year 8
Amiodarone or beta-blocker prophylaxis per institutional protocol 2, 8

Ward Phase (Days 2-5):

Daily Assessment:

Echocardiography: Predischarge TTE mandatory (97.9% maintain mild or less MR at discharge) 3
Wound inspection: Right chest incision 3-4 cm; assess for infection (lower rate than sternotomy) 5, 9
Drain management: Chest tubes typically removed when output <100 mL/8 hours 2, 3

Mobilization:

Early ambulation: Begin postoperative day 1; faster return to functional activity than sternotomy 5, 9
Mean hospital stay: 5.2-5.7 days 2, 7
Discharge destination: 95.3% discharged home (not to rehab facility) 2

Anticoagulation Management (Critical):

If Bioprosthetic Valve Replacement Performed:

Initiate IV unfractionated heparin early postoperatively with aPTT monitoring to 1.5-2.0 times control 4
Begin oral warfarin within 24-48 hours, overlapping with heparin until INR therapeutic for 2 consecutive days 4
Target INR 2.0-3.0 for minimum 3 months (regardless of LAA ligation status) 4
If atrial fibrillation present: Lifelong anticoagulation required (LAA clip does NOT eliminate need; incomplete occlusion in ~50% and thrombus forms elsewhere in LA) 4

If Mitral Valve Repair Only:

Aspirin 81-325 mg daily typically sufficient unless AF present 1, 4

Long-Term Follow-Up and Patient Education

Durability benchmarks must be communicated to patients and monitored systematically. 1, 5

Expected Outcomes:

Operative mortality: <1% (0.1-0.7% in experienced centers) 1, 7, 3
Freedom from reoperation: 95% at 15-20 years 1, 5
Freedom from recurrent moderate-severe MR: >80% at 15-20 years 1, 5
5-year survival: 96.6% 7

Follow-Up Schedule:

3 months: TTE to assess valve function, detect AF, guide anticoagulation decisions 4
Annually starting at 5 years: TTE surveillance for bioprosthetic degeneration (structural deterioration begins 7-10 years postoperatively) 4
Registry tracking: All cases, outcomes, and complications must be tracked for quality assurance 6

Patient Education:

Activity restrictions: No lifting >10 lbs for 6 weeks; no driving for 4 weeks 9
Wound care: Keep incisions clean and dry; report redness, drainage, or fever 2, 3
Endocarditis prophylaxis: Required for dental procedures for 6 months post-repair, lifelong if prosthetic valve 1
Signs of valve dysfunction: Report new dyspnea, orthopnea, edema, or palpitations immediately 4

Critical Success Factors

Hospital and surgeon volume are the single most critical determinants of success. 5, 6

High-volume centers (>140 mitral operations annually): 77% repair rate, 50% lower mortality 5, 6
Low-volume centers (<36 cases/year): 48% repair rate, significantly higher mortality 5, 6
Surgeon volume: Maintain ≥20 robotic cases/year after completing graduated training pathway 6
Team consistency: Entire team must train together; consistent tableside assistance essential 6

What are the key labs, diagnostic studies, and nursing considerations for a patient undergoing robotic Mitral Valve Repair (MVR)?

Help us tailor your experience